

GlobalBiz Outlook Magazine Features Top Companies Leading the Revolution in Cancer Diagnosis and Treatment in 2025

GlobalBiz Outlook's April edition honors Creatv Bio and other trailblazers revolutionizing cancer diagnosis and treatment across the globe in 2025

SCHAUMBURG, IL, UNITED STATES, April 23, 2025 /EINPresswire.com/ -- GlobalBiz Outlook



LifeTracDx® empowers oncologists with actionable cancer insights—offering early detection through a simple blood test.”

Dr. Cha-Mei Tang, Founder & CEO, Creatv Bio

spotlights [Creatv Bio](#), a division of Creatv MicroTech, Inc., for its groundbreaking innovations in early cancer detection. Headquartered in Potomac, Maryland, Creatv Bio is transforming cancer diagnostics with its advanced blood-based testing platform, LifeTracDx®.

Founded in 2000 by [Dr. Cha-Mei Tang](#), an MIT-trained physicist and innovator, Creatv MicroTech initially focused on microfabrication before pivoting to biomedical applications. Together with [Daniel L. Adams](#), the

company's Chief Scientific Officer, the duo developed the LifeTracDx® platform after identifying Cancer-Associated Macrophage-Like Cells (CAMLs) as early indicators of cancer—long before traditional imaging or tissue biopsies detect abnormalities.

LifeTracDx® is a revolutionary liquid biopsy that isolates and analyzes rare cancer-related cells from a standard blood sample. This technology provides insights into cancer presence, progression, and response to treatment, making it an essential tool in precision oncology.

Key applications of LifeTracDx® include:

- >Early screening for asymptomatic patients
- >Detecting minimal residual disease post-treatment
- >Identifying recurrence ahead of imaging techniques
- >Personalized treatment response tracking within 30 days

The platform uses CellSieve™ microfiltration technology to separate Circulating Tumor Cells (CTCs) and CAMLs from the bloodstream. CAMLs—large, polynucleated immune cells found only in cancer patients—serve as reliable biomarkers in over 30 cancer types, including breast, lung, colon, and prostate cancer. Their size and characteristics help determine cancer severity and

likely progression. For instance, CAMLs exceeding 50 microns often indicate aggressive disease.

Unlike traditional diagnostics that rely on invasive biopsies or expensive imaging, LifeTracDx® provides a non-invasive, real-time alternative. It gives oncologists a dynamic view of the tumor's behavior and enables timely, informed decisions about treatment plans.

Dr. Tang explains, "What we're offering is a paradigm shift in cancer care. With LifeTracDx®, we can detect cancer earlier, monitor its evolution, and adapt treatments accordingly—all through a simple blood test."

Creatv Bio's innovations extend beyond diagnostics. The technology supports companion diagnostics—such as testing for PD-L1 expression—which traditionally require tissue samples, now obtainable via blood. The platform also facilitates genomic and proteomic analyses, providing intact tumor DNA for in-depth analysis.

With over 29 peer-reviewed publications and collaborations with leading academic centers and pharmaceutical companies, Creatv Bio is gaining recognition for its scientific and clinical contributions. The company has received support from institutions such as the NIH and DARPA, further validating its impact and potential.

Dr. Adams adds, "By understanding how cancer interacts with the immune system—especially through CAMLs—we're unlocking insights that weren't accessible before. Our goal is to make early detection and personalized care accessible to all."

Creatv Bio is actively expanding its reach through clinical partnerships and is integrating AI to streamline cell analysis and data interpretation. These enhancements will support oncologists worldwide in providing timely and precise interventions.

As cancer continues to affect millions globally, Creatv Bio is leading the charge toward a future where early, accessible, and personalized diagnosis becomes the norm—not the exception.

To learn more about Creatv Bio and its LifeTracDx® technology, visit: <https://creatvbio.com>

Explore the full feature here:

□ Web Link: <https://globalbizoutlook.com/creatv-bio-pioneering-innovations-in-cancer-detection-and-diagnosis-redefining-care-to-save-lives/>

□ Digital Edition: <https://globalbizoutlook.com/top-companies-leading-the-revolution-in-cancer-diagnosis-and-treatment-2025/>

Read All our Magazine: <https://globalbizoutlook.com/magazines/>

We hope this edition inspires you with the real-world impact of science, dedication, and a

mission to save lives.

About GlobalBiz Outlook

GlobalBiz Outlook is a next-generation digital media platform connecting executive leaders and decision-makers across industries. From insightful interviews and reports to stories of innovation and success, our platform celebrates excellence and emerging technologies across sectors.

To feature your brand or request an interview reach us at info@globalbizoutlook.com Or Nominate Leadership whom you admired at: <https://globalbizoutlook.com/nomination-form/>

Sonia Saroj | Sr. Analyst, Business Development
GlobalBiz Outlook

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

[Other](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/805925978>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.